|
시장보고서
상품코드
1347207
유럽의 바이오시밀러 시장 예측(-2030년) - 적응증별, 투여 경로별, 약제 클래스별, 유통 채널별, 지역별 지역 분석Europe Biosimilars Market Forecast to 2030 - Regional Analysis By Disease Indication, Route of Administration, Drug Class, Distribution Channel, and Region |
||||||
유럽의 바이오시밀러 시장은 2022년 103억 4,486만 달러에서 2030년 1,151억 2,591만 달러로 성장할 것으로 예상되며, 2022년부터 2030년까지 연평균 35.1%의 성장률을 기록할 것으로 예상됩니다.
이 보고서는 시장 동향과 시장 성장을 촉진하는 요인에 대해 다루고 있습니다. 시장 성장의 요인은 만성 질환의 유병률 증가와 바이오시밀러 의약품의 승인 건수 증가입니다. 또한, 바이오시밀러와 임상시험을 위한 공동연구는 예측 기간 동안 시장에서 중요한 트렌드로 부상할 가능성이 높습니다. 그러나 바이오시밀러 제품 제조의 높은 비용과 복잡성은 2022-2030년 예측 기간 동안 시장 성장을 저해하는 요인으로 작용할 것입니다.
바이오시밀러와 임상시험을 위한 공동사업이 유럽 바이오시밀러 시장을 견인
합작 및 기타 제휴 모델은 향후 몇 년 동안 바이오시밀러 의약품 제조업체가 시장에서 경쟁사와의 경쟁력을 유지하는 데 도움이 될 것으로 보입니다.
바이오시밀러 의약품의 연구, 출시, 판매를 계획하고 있는 다른 기업과 협력함으로써 바이오시밀러 의약품 제조업체는 제품을 신속하게 개발하고 특허 리스크를 극복하고 임상의와 환자의 신뢰를 얻어 효과적으로 출시할 수 있습니다. 제품 개발은 국내외 전문 지식, 개발 플랫폼에 대한 접근성, 연구 및 임상시험 자금을 확보함으로써 제품 개발을 가속화할 수 있습니다.
대형 바이오의약품 제조업체와 협력하면 이미 구축된 제조 시설을 이용할 수 있습니다. 세포주 개발, 생물학적 제제 및 바이오시밀러 의약품 제조, 공정 확장, 필요한 기술 이전 등의 업무를 아웃소싱하기 위해 공동연구를 할 수 있습니다.
협업은 장기적인 이점도 있습니다. 향후 바이오시밀러 제조 프로젝트의 국내 입찰을 용이하게 하고, 조기에 효율적인 제품 개발 및 시장 개척을 가능하게 합니다. 유럽과 같이 국가별로 보건의료 정책과 시장 역학이 크게 다른 거대 시장에서는 이러한 협력을 통해 얻을 수 있는 현지 지식에 대한 접근도 매우 중요합니다.
바이오시밀러 시장의 큰 잠재력으로 인해 최근 많은 주목할 만한 공동연구가 이루어졌습니다. 그 중 몇 가지 예를 들면 다음과 같습니다:
2023년 6월, 삼성바이오로직스는 화이자와 전략적 제휴를 맺고 화이자의 여러 제품 포트폴리오를 장기적으로 상업적으로 생산하기로 했습니다. 이번 계약은 삼성바이오로직스가 화이자에 암, 염증, 면역 분야를 아우르는 다품종 바이오시밀러 의약품을 대규모로 생산할 수 있는 역량을 제공하는 것을 목표로 하고 있습니다.
2023년 5월, 노바티스의 자회사 샌드는 에보텍 바이오로직스(Evotec Biologics)와의 바이오시밀러 공동개발을 발표했습니다. 이 계약은 신속한 개발을 목표로 여러 바이오시밀러 의약품의 개발 및 후속 제조를 목표로 하고 있으며, Evotec Biologics의 시설에서 바이오시밀러 의약품 개발은 향후 12-18개월 내에 본격화될 예정입니다.
이렇게 바이오시밀러 제조와 임상시험을 위한 제조업체의 제휴는 예측 기간 동안 바이오시밀러 시장의 주요 트렌드가 될 것으로 보입니다.
블록버스터 생물학적 제제의 특허 만료로 유리한 시장 기회 제공
생물학적 제제는 불치병에 대한 유망한 새로운 치료법으로 의약품 시장에서 매우 중요한 역할을 하고 있습니다. 그러나 생물학적 제제의 특허는 향후 몇 년 내에 만료될 것으로 예상됩니다.
인기 있는 생물학적 제제의 특허 및 독점권 만료 예정일은 아래 표와 같습니다.
생물학적 제제
Avastin 2022년 1월
사이람자 2023년 5월
Adcetris 2023년 8월
Absoluxe 2024년 10월
가시바/가시바로 2024년 11월
달자렉스 2026년 5월
오크레바스 2027년 4월
엠갤러리 2028년 9월
헴리브라 2028년 2월
루르메트리 2028년 3월
임핀지 2028년 9월
Milotag 2028년 4월
임핀지 2028년 9월
미로타르그 2028년 4월
실반트 2034년 7월
출처: 제네릭 의약품 및 바이오시밀러 이니셔티브(GaBI) 저널
선행 생물학적 제제의 특허 만료 및 기타 지적재산권으로 인해 향후 새로운 바이오시밀러의 도입이 필요할 것입니다. 이에 따라 향후 몇 년 동안 업계 내 시장 경쟁은 더욱 치열해질 것으로 보입니다. 따라서 블록버스터 바이오의약품의 특허 만료는 예측 기간 동안 바이오시밀러 시장에 유리한 기회를 제공할 것으로 예상됩니다.
2022-2030년 유럽 바이오시밀러 시장은 독일이 가장 큰 점유율을 차지할 것입니다. 바이오시밀러는 경쟁을 도입하고 생물학적 제제의 구매 용이성을 향상시켜 궁극적으로 비용 절감과 부가가치 서비스를 제공하여 환자 치료 및 의료 커뮤니티를 지원합니다. 의료 전문가들은 지출을 줄이면서 더 많은 환자를 고품질 생물학적 제제로 치료할 수 있습니다. 예를 들어, Sand에 따르면, 독일에서는 2022년 바이오시밀러가 도입된 후 항TNF 약물의 일일 치료 용량이 29% 증가(1,718만 명에서 2,218만 명으로 증가)했습니다.
독일에서는 바이오시밀러가 적절한 의약품 사용의 필수적인 부분으로 지불자, 의료 제공자 및 환자들에게 받아들여지고 있습니다. 바이오시밀러에 대한 즉각적인 환자 접근을 포함하여 기업이 설정한 가격에서 완전한 상환이 이루어집니다. 독일에서는 여러 구매 그룹과 별도의 병원 체인에 의한 병원 입찰 구조로 인해 제조업체 간의 경쟁이 유지되고 있습니다. 예를 들어, 2018년 11월 독일 보건부는 의약품 공급의 안전에 관한 법안(Gesetz fur Mehr Sicherheit in der Arzneimittelversor-gung, GSAV)을 제출했습니다. 위한 법적 틀을 제공하는 것을 목표로 하고 있습니다.
비용 절감의 잠재력이 큰 만큼 독일 보건부는 바이오시밀러의 채택을 늘리기 위해 새로운 법률을 도입했습니다. 이는 특히 독일에 있어서 큰 변화를 의미하는데, 유럽연합(EU) 국가 중 바이오시밀러의 약사 대체를 허용하는 국가는 거의 없기 때문입니다. 또한 독일에서는 2019년 통과된 법률에 따라 2022년부터 연방 공동위원회(의료 보험자와 의료 서비스 제공자의 최고 의사 결정 기관)가 해당 의약품의 호환성을 판단하고 처방 의사가 명시적으로 배제하지 않는 한 약국에서 바이오시밀러를 자동으로 대체할 수 있게 될 것으로 예상됩니다. 있습니다. 이에 따라 독일에서는 바이오시밀러 도입을 위한 정부의 노력이 활발히 진행되고 있어 시장 성장이 기대되고 있습니다.
유럽 바이오시밀러 시장에서 기업들은 다양한 유기적 및 무기적 전략을 채택하고 있습니다. 유기적 전략에는 주로 제품 출시와 제품 승인이 포함됩니다. 또한, 시장에서 볼 수 있는 무기적 성장 전략에는 인수, 제휴, 파트너십 등이 있습니다. 이러한 성장 전략을 통해 시장 진입 기업은 사업을 확장하고 지리적 입지를 강화하여 전체 시장 성장에 기여할 수 있습니다. 또한, 인수 및 제휴 전략은 시장 진입자가 고객 기반을 강화하고 제품 포트폴리오를 확장하는 데 도움이 될 수 있습니다. 다음은 유럽 바이오시밀러 시장에서 주요 기업들의 주요 발전 사항 중 일부입니다.
국제당뇨병연맹, 유럽의약품청, 질병통제예방센터, 중국임상종양학, 전국포괄케어네트워크는 유럽 바이오시밀러 시장에 대한 보고서를 작성할 때 참고한 주요 1차 및 2차 정보 중 일부입니다.
목차
제1장 서론
제2장 유럽 바이오시밀러 시장 - 주요 요점
제3장 조사 방법
- 조사 범위
- 2차 조사
- 1차 조사
제4장 유럽 바이오시밀러 시장 - 시장 상황
- 개요
- 유럽 PEST 분석
- 실제 시장 가격/순 가격
- 프랑스
- 독일
- 이탈리아
- 스페인
- 영국
제5장 유럽 바이오시밀러 시장
- 시장 성장 촉진요인
- 만성질환 유병률 증가
- 바이오시밀러 승인 증가
- 시장 성장 억제요인
- 바이오시밀러 제품 제조의 고비용과 복잡성
- 시장 기회
- 블록 버스터 생물제제 특허 만료
- 향후 동향
- 바이오시밀러와 임상시험을 위한 협업
- 영향 분석
제6장 유럽 바이오시밀러 시장 - 지역 분석
- 유럽 바이오시밀러 시장 매출 예측과 분석
제7장 유럽 바이오시밀러 시장 2028년까지 분석과 예측 : 적응 질환별
- 개요
- 유럽 바이오시밀러 시장, 2022년·2030년, 적응 질환별, 매출 점유율(%)
- 암
- 당뇨병
- 자가면역질환
- 기타 질환
제8장 유럽 바이오시밀러 시장 2028년까지 분석과 예측 : 투여 경로별
- 개요
- 유럽 바이오시밀러 시장, 2022년·2030년, 투여 경로별, 매출 점유율(%)
- 정맥내 투여
- 피하 투여
- 기타
제9장 유럽 바이오시밀러 시장 : 2030년까지 매출과 예측 : 약제 클래스별
- 개요
- 유럽 바이오시밀러 시장, 2022년·2030년, 약제 클래스별, 매출 점유율(%)
- 과립구집락자극인자
- 인슐린
- TNF 차단제 및 단클론항체
- 기타
제10장 유럽 바이오시밀러 시장 : 2030년까지 매출과 예측 : 유통 채널별
- 개요
- 유럽 바이오시밀러 시장, 2022년·2030년, 유통 채널별, 매출 점유율(%)
- 내분비 전문의
- 면역학자
- 류머티즘 전문의
- 암전문의
- 피부과의
- 망막 조제
- 기타
- 병원 약국
- 조제 약국
- 소매 약국
- 온라인 약국
제11장 유럽 바이오시밀러 시장, 2030년까지 매출과 예측 - 지역 분석
제12장 COVID-19 전후의 영향
- COVID-19 전후의 영향
제13장 바이오시밀러 시장 - 업계 상황
- 바이오시밀러 시장 성장 전략
- 무기적 성장 전략
- 유기적 성장 전략
제14장 기업 개요
- Amgen Inc
- Celltrion Inc
- Sanofi SA
- Biocon Ltd
- Samsung Bioepis Co Ltd
- Eli Lilly and Co
- Sandoz AG
- Teva Pharmaceutical Industries Ltd
- Pfizer Inc
- Dr. Reddy's Laboratories Ltd
제15장 부록
ksm 23.10.25The Europe biosimilars market is expected to grow from US$ 10,344.86 million in 2022 to US$ 1,15,125.91 million by 2030; it is estimated to grow at a CAGR of 35.1% from 2022 to 2030.
The report highlights trends prevailing in the market and factors driving the market growth. The market growth is attributed to the increasing prevalence of chronic diseases and rising approvals of biosimilars. Additionally, collaborations for biosimilars and clinical trials is likely to emerge as a significant trend in the market during the forecast period. However, high cost involvement and complexities in biosimilar product manufacturing hinders market growth during the forecast period 2022-2030.
Collaborations for Biosimilars and Clinical Trials Drives the Europe Biosimilars Market
Joint ventures and other collaboration models will help biosimilar medicine manufacturers maintain a competitive edge over rivals in the market in the coming years.
By collaborating with other companies planning to research, launch, and market biosimilar drugs, biosimilar manufacturers can develop their products rapidly and launch products effectively in a way that overcomes patent risks and gains clinician and patient confidence in the product. Product development can be expedited by gaining local and foreign expertise, development platform access, and research and clinical trial funding.
Collaborating with a bigger biopharmaceutical manufacturer allows access to established manufacturing facilities. The collaboration can be done for outsourcing activities such as cell line development, biologics and biosimilar manufacturing, process scaling, and any required technology transfer.
There are long-term benefits from collaborations. They can make it easy to tender for future biosimilar production projects within the country and offer early and efficient product development and market penetration. In a sizeable market such as Europe, which has significant country-level diversity in healthcare policies and market dynamics, access to local knowledge obtained through such collaborations can also prove invaluable.
The immense potential of the biosimilars market has led to many recent, high-profile collaborations. A few instances are given below:
In June 2023, Samsung Biologics announced a strategic partnership with Pfizer for the long-term commercial manufacturing of Pfizer's multi-product portfolio. The agreement aims that Samsung Biologics will offer Pfizer additional capacity for large-scale manufacturing of a multi-product biosimilar portfolio encompassing oncology, inflammation, and immunology.
In May 2023, Sandoz, a Novartis division, announced a biosimilar collaboration with Evotec Biologics. The agreement covers developing and manufacturing multiple biosimilar medicines intended for rapid development and the subsequent manufacturing of multiple biosimilars. The development of biosimilars at the Evotec Biologics facility will ramp up under the collaboration in the next 12-18 months.
Thus, collaborations of manufacturers for biosimilar production and clinical trials will be the key trend in the biosimilar market during the forecast period.
Patent Expiry of Blockbuster Biologics Offers Lucrative Market Opportunity
Biologicals represent promising new therapies for previously incurable diseases and are becoming highly important in the pharmaceuticals market. However, patents for originator biologicals are expected to expire in the coming years.
Estimated patent and exclusivity expiry dates for best-selling biologicals are given in the following table .
Biologicals Expiry Month & Years
Avastin January 2022
Cyramza May 2023
Adcetris August 2023
Abthrax October 2024
Gazyva/Gazyvaro November 2024
Darzalex May 2026
Ocrevus April 2027
Emgality September 2028
Hemlibra February 2028
Llumetri March 2028
Imfinzi September 2028
Mylotarg April 2028
Imfinzi September 2028
Mylotarg April 2028
Sylvant July 2034
Source: Generics and Biosimilars Initiative (GaBI) Journal
The patent expiration and other intellectual property rights for originator biologicals will create a need to introduce new biosimilars in the future. As a result, competition among market players will surge in the industry in the coming years. Thus, the patent expiry of blockbuster biologics is expected to create lucrative opportunities for the biosimilar market during the forecast period.
Germany holds largest market share for the Europe biosimilars market from 2022-2030. Biosimilars introduce competition and increase the affordability of biologics, which ultimately deliver savings and value-added services to support patient care and the healthcare community. Healthcare professionals can treat more patients with high-quality biologics while reducing spending. For example, in Germany, according to Sandoz, the number of daily therapeutic doses of an anti-TNF medicine increased by 29% (from 17.18 to 22.18 million) after introducing biosimilars in 2022.
Germany has achieved acceptance of biosimilars with payers, providers, and patients as an integral part of appropriate medicine use. There is full reimbursement from a price set by the company, including immediate patient access to biosimilars. The structure of hospital tendering by multiple buying groups and separate hospital chains allows for competition among manufacturers to be maintained in Germany. For instance, in November 2018, the German Health Ministry introduced a draft bill on safety in the supply of pharmaceuticals. The Gesetz fur Mehr Sicherheit in der Arzneimittelversor-gung (GSAV) bill aims to provide a legal framework for the automatic substitution of biosimilars by pharmacists in Germany.
Due to the huge potential for cost savings, the German Health Ministry introduced a new law to increase the adoption of biosimilars. As few European Union (EU) countries allow pharmacist substitution of biosimilars, this would represent a significant change in practice, particularly for Germany. Additionally, in Germany, a law passed in 2019 foresees the automatic substitution of biosimilars in pharmacies beginning in 2022, provided the Federal Joint Committee (the highest decision-making body of the self-governance of health insurers and providers) has determined the interchangeability of the medicines in question, and the prescribing physician has not explicitly excluded it. Therefore, with the growing government initiatives for adopting biosimilars in Germany, the market is expected to grow.
Various organic and inorganic strategies are adopted by companies in the Europe biosimilars market. The organic strategies mainly include product launches and product approvals. Further, inorganic growth strategies witnessed in the market are acquisitions, collaborations, and partnerships. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall market growth. Further, acquisition and partnership strategies help the market players strengthen their customer base and expand their product portfolios. A few of the significant developments by key players in the Europe biosimilars market are listed below.
International Diabetes Federation, European Medicine Agency, Centers for Disease Control and Prevention, Chinese Clinical Oncology, National Comprehensive Care Network are a few of the major primary and secondary sources referred to while preparing the report on the Europe biosimilars market.
Reasons to Buy:
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe biosimilars market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the global Europe biosimilars market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.
Table Of Contents
1. Introduction
- 1.1 The Insight Partners Research Report Guidance
- 1.2 Market Segmentation
2. Europe Biosimilars Market - Key Takeaways
3. Research Methodology
- 3.1 Coverage
- 3.2 Secondary Research
- 3.3 Primary Research
4. Europe Biosimilars Market - Market Landscape
- 4.1 Overview
- 4.1.1 Europe PEST Analysis
- 4.2 Actual Market Price/Net Price
- 4.2.1 France
- 4.2.2 Germany
- 4.2.3 Italy
- 4.2.4 Spain
- 4.2.5 UK
5. Europe Biosimilars Market
- 5.1 Market Drivers
- 5.1.1 Increasing Prevalence of Chronic Diseases
- 5.1.2 Rising Approvals of Biosimilars
- 5.2 Market Restraints
- 5.2.1 High Cost Involvement and Complexities in Biosimilar Product Manufacturing
- 5.3 Market Opportunities
- 5.3.1 Patent Expiry of Blockbuster Biologics
- 5.4 Future Trends
- 5.4.1 Collaborations for Biosimilars and Clinical Trials
- 5.5 Impact analysis
6. Europe Biosimilars Market - Regional Analysis
- 6.1 Europe Biosimilars Market Revenue Forecast and Analysis
7. Europe Biosimilars Market - Revenue and Forecast to 2030 - by Disease Indication
- 7.1 Overview
- 7.2 Europe Biosimilars Market Revenue Share, by Type 2022 & 2030 (%)
- 7.3 Cancer
- 7.3.1 Overview
- 7.3.2 Cancer: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 7.4 Diabetes
- 7.4.1 Overview
- 7.4.2 Diabetes: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 7.5 Autoimmune Diseases
- 7.5.1 Overview
- 7.5.2 Autoimmune Diseases: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 7.5.3 Psoriasis
- 7.5.3.1 Overview
- 7.5.4 Psoriasis: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 7.5.5 Arthritis
- 7.5.5.1 Overview
- 7.5.6 Arthritis: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 7.5.7 Others
- 7.5.7.1 Overview
- 7.5.7.2 Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 7.6 Other Disease Indication
- 7.6.1 Overview
- 7.6.2 Other Disease Indication: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
8. Europe Biosimilars Market Analysis and Forecasts to 2028 - by Route of Administration
- 8.1 Overview
- 8.2 Europe Biosimilars Market, by Route of Administration 2022 & 2030 (%)
- 8.3 Intravenous
- 8.3.1 Overview
- 8.3.2 Intravenous: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 8.4 Subcutaneous
- 8.4.1 Overview
- 8.4.2 Subcutaneous: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 8.5 Others
- 8.5.1 Overview
- 8.5.2 Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
9. Europe Biosimilars Market - Revenue and Forecast to 2030 - by Drug Class
- 9.1 Overview
- 9.2 Europe Biosimilars Market Revenue Share, by Drug Class 2022 & 2030 (%)
- 9.3 Granulocyte Colony-Stimulating Factor
- 9.3.1 Overview
- 9.3.2 Granulocyte Colony-Stimulating Factor: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 9.4 Insulin
- 9.4.1 Overview
- 9.4.2 Insulin: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 9.5 TNF Blockers and Monoclonal Antibodies
- 9.5.1 Overview
- 9.5.2 TNF Blockers and Monoclonal Antibodies: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 9.6 Others
- 9.6.1 Overview
- 9.6.2 Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
10. Europe Biosimilars Market - Revenue and Forecast to 2030 - by Distribution Channel
- 10.1 Overview
- 10.2 Europe Biosimilars Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
- 10.3 Endocrinologists
- 10.3.1 Overview
- 10.4 Immunologists
- 10.4.1 Overview
- 10.5 Rheumatologists
- 10.5.1 Overview
- 10.6 Oncologists
- 10.6.1 Overview
- 10.7 Dermatologists
- 10.7.1 Overview
- 10.8 Retina Compounding
- 10.8.1 Overview
- 10.9 Others
- 10.9.1 Overview
- 10.10 Hospital Pharmacies
- 10.10.1 Overview
- 10.10.2 Hospital Pharmacies: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.10.3 Endocrinologists
- 10.10.3.1 Endocrinologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.10.4 Immunologists
- 10.10.4.1 Immunologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.10.5 Rheumatologists
- 10.10.5.1 Rheumatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.10.6 Oncologists
- 10.10.6.1 Oncologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.10.7 Dermatologists
- 10.10.7.1 Dermatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.10.8 Retina Specialists
- 10.10.8.1 Retina Specialists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.10.9 Others
- 10.10.9.1 Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.11 Compounding Pharmacies
- 10.11.1 Overview
- 10.11.2 Compounding Pharmacies : Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.11.3 Endocrinologists
- 10.11.3.1 Endocrinologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.11.4 Immunologists
- 10.11.4.1 Immunologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.11.5 Rheumatologists
- 10.11.5.1 Rheumatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.11.6 Oncologists
- 10.11.6.1 Oncologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.11.7 Dermatologists
- 10.11.7.1 Dermatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.11.8 Retina Specialists
- 10.11.8.1 Retina Specialists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.11.9 Others
- 10.11.9.1 Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.12 Retail Pharmacies
- 10.12.1 Overview
- 10.12.2 Retail Pharmacies: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.12.3 Endocrinologists
- 10.12.3.1 Endocrinologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.12.4 Immunologists
- 10.12.4.1 Immunologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.12.5 Rheumatologists
- 10.12.5.1 Rheumatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.12.6 Oncologists
- 10.12.6.1 Oncologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.12.7 Dermatologists
- 10.12.7.1 Dermatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.12.8 Retina Specialists
- 10.12.8.1 Retina Specialists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.12.9 Others
- 10.12.9.1 Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.13 Online Pharmacies
- 10.13.1 Overview
- 10.13.2 Online Pharmacies: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.13.3 Endocrinologists
- 10.13.3.1 Endocrinologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.13.4 Immunologists
- 10.13.4.1 Immunologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.13.5 Rheumatologists
- 10.13.5.1 Rheumatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.13.6 Oncologists
- 10.13.6.1 Oncologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.13.7 Dermatologists
- 10.13.7.1 Dermatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.13.8 Retina Specialists
- 10.13.8.1 Retina Specialists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
- 10.13.9 Others
- 10.13.9.1 Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
11. Europe Biosimilars Market - Revenue and Forecast to 2030 - Geographic Analysis
- 11.1 Europe Biosimilars Market, Revenue and Forecast to 2030
- 11.1.1 Overview
- 11.1.2 Europe Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
- 11.1.2.1 Europe Biosimilars Market, by Disease Indication
- 11.1.2.2 Europe Biosimilars Market, by Autoimmune Diseases
- 11.1.2.3 Europe Biosimilars Market, by Route of Administration
- 11.1.2.4 Europe Biosimilars Market, by Drug Class
- 11.1.2.5 Europe Biosimilars Market, by Distribution Channel
- 11.1.2.6 Europe Biosimilars Market, by Hospital Pharmacies
- 11.1.2.7 Europe Biosimilars Market, by Compounding Pharmacies
- 11.1.2.8 Europe Biosimilars Market, by Retail Pharmacies
- 11.1.2.9 Europe Biosimilars Market, by Online Pharmacies
- 11.1.2.10 Europe Biosimilars Market by Country
- 11.1.2.10.1 Germany
- 11.1.2.10.1.1 Overview
- 11.1.2.10.1.2 Germany Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
- 11.1.2.10.1.2.1 Germany Biosimilars Market, by Disease Indication
- 11.1.2.10.1.2.2 Germany Biosimilars Market, by Autoimmune Diseases
- 11.1.2.10.1.2.3 Germany Biosimilars Market, by Route of Administration
- 11.1.2.10.1.2.4 Germany Biosimilars Market, by Drug Class
- 11.1.2.10.1.2.5 Germany Biosimilars Market, by Distribution Channel
- 11.1.2.10.1.2.6 Germany Biosimilars Market, by Hospital Pharmacies
- 11.1.2.10.1.2.7 Germany Biosimilars Market, by Compounding Pharmacies
- 11.1.2.10.1.2.8 Germany Biosimilars Market, by Retail Pharmacies
- 11.1.2.10.1.2.9 Germany Biosimilars Market, by Online Pharmacies
- 11.1.2.10.2 UK
- 11.1.2.10.3 Overview
- 11.1.2.10.3.1 UK Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
- 11.1.2.10.3.1.1 UK Biosimilars Market, by Disease Indication
- 11.1.2.10.3.1.2 UK Biosimilars Market, by Autoimmune Diseases
- 11.1.2.10.3.1.3 UK Biosimilars Market, by Route of Administration
- 11.1.2.10.3.1.4 UK Biosimilars Market, by Drug Class
- 11.1.2.10.3.1.5 UK Biosimilars Market, by Distribution Channel
- 11.1.2.10.3.1.6 UK Biosimilars Market, by Hospital Pharmacies
- 11.1.2.10.3.1.7 UK Biosimilars Market, by Compounding Pharmacies
- 11.1.2.10.3.1.8 UK Biosimilars Market, by Retail Pharmacies
- 11.1.2.10.3.1.9 UK Biosimilars Market, by Online Pharmacies
- 11.1.2.10.4 France
- 11.1.2.10.4.1 Overview
- 11.1.2.10.4.2 France Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
- 11.1.2.10.4.2.1 France Biosimilars Market, by Disease Indication
- 11.1.2.10.4.2.2 France Biosimilars Market, by Autoimmune Diseases
- 11.1.2.10.4.2.3 France Biosimilars Market, by Route of Administration
- 11.1.2.10.4.2.4 France Biosimilars Market, by Drug Class
- 11.1.2.10.4.2.5 France Biosimilars Market, by Distribution Channel
- 11.1.2.10.4.2.6 France Biosimilars Market, by Hospital Pharmacies
- 11.1.2.10.4.2.7 France Biosimilars Market, by Compounding Pharmacies
- 11.1.2.10.4.2.8 France Biosimilars Market, by Retail Pharmacies
- 11.1.2.10.4.2.9 France Biosimilars Market, by Online Pharmacies
- 11.1.2.10.5 Italy
- 11.1.2.10.5.1 Overview
- 11.1.2.10.5.2 Italy Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
- 11.1.2.10.5.2.1 Italy Biosimilars Market, by Disease Indication
- 11.1.2.10.5.2.2 Italy Biosimilars Market, by Autoimmune Diseases
- 11.1.2.10.5.2.3 Italy Biosimilars Market, by Route of Administration
- 11.1.2.10.5.2.4 Italy Biosimilars Market, by Drug Class
- 11.1.2.10.5.2.5 Italy Biosimilars Market, by Distribution Channel
- 11.1.2.10.5.2.6 Italy Biosimilars Market, by Hospital Pharmacies
- 11.1.2.10.5.2.7 Italy Biosimilars Market, by Compounding Pharmacies
- 11.1.2.10.5.2.8 Italy Biosimilars Market, by Retail Pharmacies
- 11.1.2.10.5.2.9 Italy Biosimilars Market, by Online Pharmacies
- 11.1.2.10.6 Spain
- 11.1.2.10.6.1 Overview
- 11.1.2.10.6.2 Spain Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
- 11.1.2.10.6.2.1 Spain Biosimilars Market, by Disease Indication
- 11.1.2.10.6.2.2 Spain Biosimilars Market, by Autoimmune Diseases
- 11.1.2.10.6.2.3 Spain Biosimilars Market, by Route of Administration
- 11.1.2.10.6.2.4 Spain Biosimilars Market, by Drug Class
- 11.1.2.10.6.2.5 Spain Biosimilars Market, by Distribution Channel
- 11.1.2.10.6.2.6 Spain Biosimilars Market, by Hospital Pharmacies
- 11.1.2.10.6.2.7 Spain Biosimilars Market, by Compounding Pharmacies
- 11.1.2.10.6.2.8 Spain Biosimilars Market, by Retail Pharmacies
- 11.1.2.10.6.2.9 Spain Biosimilars Market, by Online Pharmacies
- 11.1.2.10.7 Rest of Europe
- 11.1.2.10.7.1 Overview
- 11.1.2.10.7.2 Rest of Europe Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
- 11.1.2.10.7.2.1 Rest of Europe Biosimilars Market, by Disease Indication
- 11.1.2.10.7.2.2 Rest of Europe Biosimilars Market, by Autoimmune Diseases
- 11.1.2.10.7.2.3 Rest of Europe Biosimilars Market, by Route of Administration
- 11.1.2.10.7.2.4 Rest of Europe Biosimilars Market, by Drug Class
- 11.1.2.10.7.2.5 Rest of Europe Biosimilars Market, by Distribution Channel
- 11.1.2.10.7.2.6 Rest of Europe Biosimilars Market, by Hospital Pharmacies
- 11.1.2.10.7.2.7 Rest of Europe Biosimilars Market, by Compounding Pharmacies
- 11.1.2.10.7.2.8 Rest of Europe Biosimilars Market, by Retail Pharmacies
- 11.1.2.10.7.2.9 Rest of Europe Biosimilars Market, by Online Pharmacies
12. Pre and Post COVID-19 Impact
- 12.1 Pre and Post COVID-19 Impact
13. Biosimilars Market - Industry Landscape
- 13.1 Overview
- 13.2 Growth Strategies in Biosimilars Market
- 13.3 Inorganic Growth Strategies
- 13.3.1 Overview
- 13.4 Organic Growth Strategies
- 13.4.1 Overview
14. Company Profiles
- 14.1 Amgen Inc
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
- 14.2 Celltrion Inc
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
- 14.3 Sanofi SA
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.4 Biocon Ltd
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
- 14.5 Samsung Bioepis Co Ltd
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
- 14.6 Eli Lilly and Co
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
- 14.7 Sandoz AG
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
- 14.8 Teva Pharmaceutical Industries Ltd
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
- 14.9 Pfizer Inc
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments
- 14.10 Dr. Reddy's Laboratories Ltd
- 14.10.1 Key Facts
- 14.10.2 Business Description
- 14.10.3 Products and Services
- 14.10.4 Financial Overview
- 14.10.5 SWOT Analysis
- 14.10.6 Key Developments
15. Appendix
- 15.1 About The Insight Partners
- 15.2 Glossary of Terms
